ADVA
ADVA (FSE: ADV) today announced that it is playing a key role in a unique research initiative extending post-quantum security to VPN networks. Leveraging the ADVA FSP 150 with ConnectGuard™ Ethernet encryption, the Quantum-Secure VPN Modules and Operation Modes (QuaSiModO) project is testing new quantum-resistant algorithms in the packet domain. It will develop viable security solutions that can protect Layer 2 and 3 data against all forms of cyberattack, including those from quantum computers. By participating in the initiative, ADVA is extending its industry-leading work with quantum-safe cryptography in optical transport to higher network layers. Other QuaSiModO project partners are the Fraunhofer Institute of Applied and Integrated Security, the Ludwig Maximilian University of Munich and genua GmbH.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200512005043/en/
“As part of the QuaSiModO project, we’re continuing to drive innovation in future-proof cryptography. This initiative extends comprehensive post-quantum security to VPNs and enables businesses and government institutions to protect their data from tomorrow’s attacks,” said Jörg-Peter Elbers, SVP, advanced technology, ADVA. “Together with our partners, we’re ensuring that network security technology doesn’t fall behind in the computing power race. Our role in the project combines our experience with transport layer post-quantum security and our proven expertise when it comes to encrypting Carrier Ethernet connectivity. We’re helping to create a solution able to protect packet services today and ready to be upgraded later to comply with emerging specifications from standards bodies such as the USA’s National Institute of Standards and Technology.”
Quantum computers of sufficient size and reliability could arrive within the next 10 to 15 years. This may mean that today’s widely applied data protection technologies will no longer be sufficient. What’s more, sensitive and valuable information may be at risk right now from harvesting attacks, with attackers storing information today to decrypt it as soon as large quantum computers are available. Funded by the German Federal Ministry of Education and Research, the QuaSiModO project is researching, testing and helping to standardize quantum-resistant algorithms in VPN implementations. It aims to extend existing IPSec and MACsec communication protocols with quantum-resistant procedures and support the development of complete solutions. The initiative is utilizing ADVA FSP 150 edge devices with ConnectGuard™ Ethernet encryption technology based on an enhanced version of MACsec. The solution provides high throughput and low-latency performance as it encrypts across multiple domains and service provider networks.
“When quantum computers emerge, they’ll be able to quickly crack complex problems that would take today’s most powerful supercomputers many years to solve. That’s why enterprises, governments and communication service providers are looking to leverage security technology built on quantum-safe algorithms,” commented Alexander von Gernler, head of research, genua GmbH. “For a decade, we’ve been focused on the threat posed by large quantum computers, and much of our work in recent years has been about developing practical quantum-resistant signatures and key establishment protocols. Now, we’re leading the QuaSiModO consortium, working with ADVA and the other partners to bring post-quantum security to network Layers 2 and 3, and deliver the robust future-proof protection that classical encryption technologies simply can’t.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200512005043/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cross-Border Private Credit Set to Surge, But Operational Complexity Threatens Momentum, CSC Finds4.12.2025 14:30:00 CET | Press release
79% of GPs expect cross-border private credit deals to grow over the next three years, with more than half forecasting rapid acceleration40% of LPs rejected private credit investment opportunities last year due to reporting or operational concerns92% of LPs say specialist outsourcing enhances transparency Cross-border private credit transactions are poised for strong growth, yet operational complexity is emerging as a critical hurdle. According to CSC, the leading provider of business administration and compliance solutions, an overwhelming 92% of limited partners (LPs) express concern over the complexity of these deals. Published in CSC’s latest report, Private Credit 2025: Global Strategies for a $1.5 Trillion Market, the findings highlight a growing disconnect between investors and fund managers as private credit continues its rapid international expansion. 1 While both LPs and general partners (GPs) remain optimistic about the growth of cross-border private credit, they diverge sha
Pace selected by Prudential Financial to help automate its insurance operations with agentic AI4.12.2025 14:15:00 CET | Press release
Pace’s AI-powered agents are helping to streamline policy service and perform other quality assurance tasks within Prudential’s Individual Life Insurance business Pace, the agentic workforce for insurance, was chosen by Prudential’s Individual Life Insurance (ILI) business to help simplify and improve its service delivery. Pace’s AI-powered agents are now streamlining policy servicing and supporting quality assurance efforts within Prudential’s ILI business. The first set of automated systems is now live taking on thousands of hours of work. “Our work with Prudential is an example of how AI can be used as a strategic advantage,” said Pace CEO Jamie Cuffe. “We’re thrilled to support their exceptional team with AI agents in production today that deliver best-in-class accuracy and speed at significant scale.” This multi-year agreement between Pace and Prudential’s ILI business began as a pilot and quickly moved to full production after demonstrating clear improvements in speed and operati
Redefining Acromegaly Care: First Patient Randomized in Debiopharm’s Phase III OXTEND-03™ Trial of 3-Month Debio 4126 Treatment4.12.2025 14:00:00 CET | Press release
OXTEND-03™ (NCT06930625) is a Phase III, multi-center, randomized trial assessing the efficacy and safety of Debio 4126, the first and only octreotide formulation designed for quarterly (3-month) dosing Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company committed to establishing tomorrow’s standards of care in oncology and rare diseases, today announced that the first patient has been randomized in the OXTEND-03™ clinical trial. This pivotal Phase III trial is designed to evaluate the efficacy and safety of Debio 4126, a novel long-acting octreotide formulation and the first potential 3-month somatostatin analogue (SSA), in adults with acromegaly who are currently maintained on somatostatin analogs. OXTEND-03™ is a global trial spanning approximately 75 sites across 21 countries, aiming to enroll around 120 patients. The primary goal of the trial is to confirm Debio 4126’s ability to maintain biochemical control of the disease while significantly
Visa Launches Global Art Collection to Elevate Creators and Celebrate the FIFA World Cup 26™4.12.2025 14:00:00 CET | Press release
Visa spotlights global illustrators and creative small businesses, teaming up with Pharrell Williams’ JOOPITER to accelerate creator growth. Visa today unveiled the first five pieces in its first-ever global art collection celebrating the cultural energy of the FIFA World Cup 26™. Featuring more than twenty artists from six continents, the collection reflects Visa’s belief that creativity drives commerce—and that today’s creators are the entrepreneurs shaping communities and culture around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204080105/en/ Darien Birks (Global) Visa debuted the first five pieces in the collection at an exclusive Miami showcase, “The Art of the Draw”, hosted by multidisciplinary creator KidSuper. The showcase featured the works of artists Darien Birks, Nathan Walker, Cesar Canseco, Ivan Roque, and Rafael Mayani that celebrate the culture and traditions of each host country and host cit
Parse Biosciences Launches Evercode Whole Blood Fixation4.12.2025 14:00:00 CET | Press release
New fixation method streamlines blood sample handling for translational research Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the launch of Evercode™ Whole Blood Fixation, a new kit that enables immediate fixation of whole blood directly at the point of collection. The technology eliminates the need for on-site PBMC isolation, specialized equipment, or trained personnel, allowing translational hematology and pharmaceutical research teams to seamlessly collect blood samples in real-world clinical settings for downstream single cell analysis. Traditional single cell RNA profiling workflows done in a translational setting require a compromise between processing fresh samples, which degrade rapidly and demand skilled handling, and using fixation approaches that capture only a partial transcriptome and cannot provide paired TCR sequences. Fresh PBMC isolation also requires complex workflows and specialized reagents. Everc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom